Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2013

View Archived Issues

MIR146A gene polymorphisms linked to atrial fibrillation prognosis

Presentation of the data from clinical trials of dulaglutide

Development of an antimalaria vaccine that targets disease transmission

Data from the clinical evaluation of a prophylactic therapy for patients with hemophilia B

Teva enters collaboration with Israeli academic institutions in neurodegenerative disease

North Carolina State University discloses new agents for bacterial infections

Researchers at Roche present novel tyrosine-protein kinase inhibitors

Teva and Lonza decide to discontinue joint venture in biosimilars

Roche synthesizes novel TAAR1 ligands

Candesartan is as effective as propranolol for preventing migraine

Invion begins phase II INV-102 trial

FDA approves Fetzima for major depressive disorder in adults

CHMP confirms Xeljanz recommendation

Thrombomodulin downregulated thrombin generation mediators/markers in sepsis-associated coagulopathy

New FSH receptor agonists disclosed by Merck KGaA for female infertility

AstraZeneca and Bristol-Myers Squibb resubmit NDA for dapagliflozin

Curis commences phase I study of CUDC-427 in advanced malignancies

Diazyme obtains 510(k) clearance from FDA to market its myoglobin assay

Jiangsu Hengrui Medicine synthesizes novel GPR40 agonists

Kyowa Hakko Kirin Korea begins patient recruitment in phase I/II study of BIW-8962 in lung cancer

Researchers at X-Rx/X-Chem report new tyrosine-protein kinase BTK inhibitors

Phase III orteronel study in metastatic castration-resistant prostate cancer unblinded

IND approved for oncolytic agent 3-bromopyruvate

InSite Vision reports topline results from DOUBle phase III study in blepharitis

Tesaro begins phase III trial of niraparib for treatment of ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...